Adverse effects associated with the short-term treatment of panic disorder with imipramine, alprazolam or placebo

@article{Cassano1994AdverseEA,
  title={Adverse effects associated with the short-term treatment of panic disorder with imipramine, alprazolam or placebo},
  author={G. Cassano and C. Toni and A. Petracca and J. Deltito and O. Benkert and G. Curtis and H. Hippius and W. Maier and D. Shera and G. Klerman},
  journal={European Neuropsychopharmacology},
  year={1994},
  volume={4},
  pages={47-53}
}
Side effects play a significant role in the selection of drugs to be used in panic disorder/agoraphobia whose polyphobic symptomatology often includes a suspiciousness about taking drugs and a fear of undesired side effects which may lead to the refusal of treatment. The safety, side effects and patients' acceptance of alprazolam and imipramine versus placebo were evaluated in 1168 subjects with panic disorder/agoraphobia who had been enrolled in the second phase of the Upjohn World Wide Panic… Expand
Clinical pharmacology, clinical efficacy, and behavioral toxicity of alprazolam: a review of the literature.
TLDR
An exhaustive review of the literature showed that alprazolam is significantly superior to placebo, and is at least equally effective in the relief of symptoms as tricyclic antidepressants (TCAs) such as imipramine. Expand
Sertraline in the treatment of panic disorder. A multi-site, double-blind, placebo-controlled, fixed-dose investigation.
TLDR
Sertraline was effective and safe in reducing panic attacks and dry mouth and ejaculation failure (primarily ejaculation delay) were associated significantly with sERTraline. Expand
Benzodiazepines in Panic Disorder
TLDR
It is very important to include this class of drugs in the armamentarium for treating PD because the benzodiazepines are efficacious in PD and the physician can manage the concern about dependence and withdrawal. Expand
Antidepressants versus placebo for panic disorder in adults.
TLDR
Low-quality evidence was found that revealed a benefit for antidepressants as a group in comparison with placebo in terms of efficacy measured as failure to respond, and treatment acceptability, measured by total number of dropouts for any reason. Expand
Selective serotonin reuptake inhibitors and benzodiazepines in panic disorder: A meta-analysis of common side effects in acute treatment
TLDR
Overall, the meta-analysis showed that SSRIs cause more adverse events than BZs in short-term PD treatment, and clinical guidelines based on incontrovertible evidence are needed. Expand
The role of alprazolam for the treatment of panic disorder in Australia
TLDR
Alprazolam has shown efficacy for control of PD symptoms, particularly in short-term controlled clinical trials, but is no longer recommended as a first-line pharmacological treatment due to concerns about the risks of developing tolerance, dependence and abuse potential. Expand
Antidepressants and benzodiazepines for panic disorder in adults.
TLDR
Low-quality evidence suggested no difference between antidepressants and benzodiazepines in terms of response rate and confidence interval, and some evidence suggesting that serotonin reuptake inhibitors (SSRIs) are better tolerated than TCAs (when looking at the number of patients experiencing adverse effects). Expand
Benzodiazepines versus placebo for panic disorder in adults.
TLDR
Two primary outcomes of efficacy and acceptability showed a possible advantage of benzodiazepines over placebo, and the quality of the evidence as low for both primary outcomes was assessed. Expand
ALPRAZOLAM: profilo farmacoeconomico nei disturbi d’ansia e da attacchi di panico
TLDR
The clinical pharmacology and the therapeutic profile of alprazolam are reviewed and analysed under the pharmacoeconomic perspectives of the italian patients, General Practitioners, NHS and society. Expand
Effects of antidepressant treatment on the quality of daily life: an experience sampling study.
TLDR
ESM provides new insights in the effects of antidepressant treatment on daily life experiences and should therefore be considered as a supplement to conventional instruments in clinical trials. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 37 REFERENCES
Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. II. Patient acceptance, side effects, and safety.
TLDR
Treatment-related side effects that were worse in patients taking alprazolam than in those taking placebo included sedation, fatigue, ataxia, slurred speech, and amnesia, which tended to subside with dose reduction or continued administration of the drug. Expand
Drug treatment of panic disorder: the comparative efficacy of imipramine, alprazolam, and trazodone.
TLDR
The different time courses of therapeutic action of imipramine and alprazolam indicate that these drugs ameliorate panic anxiety via different mechanisms, and support the hypotheses that drugs that are efficacious in the treatment of panic disorders act by altering noradrenergic function and that drugs with primary actions on serotonin function are likely to be less effective treatments. Expand
High-potency benzodiazepines for short-term management of panic disorder: the U.S. experience.
  • G. Tesar
  • Medicine
  • The Journal of clinical psychiatry
  • 1990
TLDR
Alprazolam is comparable to but more rapid than antidepressants in its effects and better tolerated and the morbidity and mortality associated with panic disorder suggest that the benefits of benzodiazepine treatment outweigh its risks. Expand
Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. I. Efficacy in short-term treatment.
TLDR
Alprazolam was found to be effective and well tolerated in patients with agoraphobia with panic attacks and panic disorder and significantly more placebo recipients subsequently dropped out of the trial, primarily citing ineffectiveness of placebo as the reason. Expand
Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. III. Discontinuation effects.
TLDR
It is recommended that patients with panic disorder be treated for a longer period, at least six months, and that medication be tapered over a more prolonged period, for at least eight weeks, especially where high doses are employed. Expand
Maintenance drug treatment of panic disorder. I. Results of a prospective, placebo-controlled comparison of alprazolam and imipramine.
TLDR
Alprazolam therapy was effective and well tolerated at a mean daily dose of 5.7 mg and Imipramine hydrochloride (175 mg/d) also produced significant panic relief but was associated with poor patient acceptance. Expand
Problems with tricyclic antidepressant use in patients with panic disorder or agoraphobia: results of a naturalistic follow-up study.
TLDR
Patients with panic disorder or agoraphobia with panic attacks who had been placed on a regimen of tricyclic antidepressant treatment 1 to 4 years earlier reported at least moderate improvement during treatment; however, side effects were often difficult to tolerate, and 35% discontinued tricycleclic treatment on this account. Expand
Maintenance drug therapy of panic disorder.
TLDR
The data suggest sustained efficacy and safety of imipramine and alprazolam over an extended period and suggest that tolerance does not develop to the therapeutic effects of either drug. Expand
Clomipramine for panic disorder: I. The first 10 weeks of a long-term comparison with imipramine.
TLDR
Both tricyclics and clomipramine were found to be markedly and equally effective for blocking panic attacks, alleviating phobic avoidance, and reducing nonspecific aspects of anxiety. Expand
A comparison of fluvoxamine, cognitive therapy, and placebo in the treatment of panic disorder.
TLDR
Fluvoxamine was found to be an effective and well-tolerated treatment for panic using clinician- and patient-rated variables and cognitive therapy was not superior to fluvoxamine on any rating. Expand
...
1
2
3
4
...